Section Arrow
MOLN.NASDAQ
- Molecular Partners AG
Quotes are at least 15-min delayed:2026/04/15 22:31 EDT
Regular Hours
Last
 4.2
+0.06 (+1.45%)
Day High 
4.2 
Prev. Close
4.14 
1-M High
5.0099 
Volume 
1.09K 
Bid
3.5
Ask
6.27
Day Low
4.15 
Open
4.15 
1-M Low
3.71 
Market Cap 
154.88M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.06 
20-SMA 4.23 
50-SMA 4.49 
52-W High 5.36 
52-W Low 3.36 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.65/-1.35
Enterprise Value
157.32M
Balance Sheet
Book Value Per Share
2.72
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.25
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.544+0.2292+72.81%-- 
LIMNLiminatus Pharma Inc0.1856+0.0058+3.23%-- 
PPCBPropanc Biopharma Inc0.1106+0.0131+13.44%0PE
ALLOAllogene Therapeutics2.17-0.11-4.82%-- 
CUECue Biopharma0.7243+0.2863+65.37%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPintherapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.